Overall Study Design Sample Clauses

Overall Study Design. This is a randomized, single-blind, placebo-controlled, QD dose study of CRV431 in presumed XXXX F2/F3 subjects. This study will consist of 3 phases: (i) Screening and Randomization; (ii) treatment; and (iii) follow up.
Sample 1
AutoNDA by SimpleDocs
Overall Study Design. This double-blind, randomized, placebo-controlled trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with WHO Group I CTD-PAH. Qualified patients will be randomized 1:1 to either bardoxolone methyl or placebo to be administered once daily for 24 weeks. Patients randomized to placebo will remain on placebo throughout the study and undergo sham titration. Patients randomized to bardoxolone methyl will start at 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically. Dose de-escalation is permitted during the study if indicated clinically. Please refer to Section 7.3.1 for additional details on dose escalation and dose de-escalation. All patients in the study will follow the same visit and assessment schedule. Following randomization, patients will be scheduled to be assessed in person during treatment at Weeks 1, 2, 4, 6, 8, 16, and 24 and by telephone contact on Days 3, 10, 21, 31, 38, 84, and 140. Patients will also be scheduled to be assessed at an in-person follow up visit at Week 28, four weeks after the end of treatment. Patients who complete the study and are treatment-compliant to their assigned dose will be eligible for a separate open-label extension study.
Sample 1
Overall Study Design. This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec containing 2 grams of secnidazole in female patients with trichomoniasis. Approximately 144 patients who test positive for trichomonas on OSOM® rapid test or via wet mount assessment or have positive T. vaginalis NAAT test within 30 days of screening (and have not been treated) and fulfill other eligibility criteria at the baseline visit will be enrolled in this study. The diagnosis of T. vaginalis will be confirmed by a positive culture for T. vaginalis. The study will consist of a primary study phase (Visit 1 (baseline) to Visit 2 (Day 6-12)) and a follow-up phase (Visit 2 to Visit 3 (7-12 days post Visit 2)). During the primary phase patients will be randomly assigned in a 1:1 ratio to either Solosec or placebo. The randomization will be stratified by site and based on the clinical symptoms of trichomoniasis (present or absent). Patients will return to the clinic for the “test of cure” (TOC) visit to be conducted on Days 6-12 (Visit 2). After all Visit 2 (V2) study procedures have been completed, patients will receive the opposite treatment (placebo patients will receive Solosec and vice versa). Patients with V2 cultures that are subsequently positive for T. vaginalis will return to the clinic for Visit 3 (V3) assessments and investigator assessment of need for additional therapy (an additional Visit 4 may be scheduled at the investigator’s discretion if culture at V3 is positive). Patients with cultures that are negative at V2 will be contacted by phone and discharged from the study (no V3 required). A Schedule of Assessments is provided in Table 1.
Sample 1
Overall Study Design. This is a randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of SAGE-217 in adults diagnosed with severe PPD. Participants, site staff, and sponsor personnel will be masked to treatment allocation. This study will consist of a Screening Period of up to 28 days, a 14-day double-blind Treatment Period and a Follow-up Period through Day 45. The Screening Period begins with the signing of the informed consent form (ICF); the ICF must be signed prior to beginning any screening activities. The diagnosis of depression will be determined using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) Axis I Disorders (SCID-5-CT). Participants will undergo preliminary screening procedures to determine eligibility. A full personal medical history will be taken including documentation of all major depression episodes, other Axis I disorders, and any prior PPD episodes. In addition, PPD episodes experienced by immediate female family members, including siblings, parents, and grandparents will be documented. During the study, a qualified lactation consultant will be made available upon request to participants who are breastfeeding. Psychotropic medications are permitted provided participants are on a stable dose for at least 30 days prior to Day 1 and agree to continue on a stable dose through completion of the Day 45 assessments. Initiation of new psychotropic medications that may potentially have an impact on efficacy and/or safety endpoints will not be allowed within 30 days prior to Day 1 through completion of the Day 45 assessments. On Day 1, eligible participants will be stratified based on use of antidepressant treatment (current/stable or not treated/withdrawn ≥30 days or >5 half-lives) and randomized within each stratum to one of 2 treatment groups (SAGE-217 50 mg or matching placebo) in a 1:1 ratio. Participants will self-administer investigational product (IP) once daily at approximately 8 PM with fat-containing food (eg, within 1 hour of an evening meal which contains fat, or with a fat-containing snack), on an outpatient basis, for 14 days. See Section 10.5 for examples of fat-containing snacks. As local regulations permit, IP administration will be monitored via a medication adherence monitoring platform used on smartphones to visually confirm IP ingestion. Participants will return to the study center during the treatment and follow-up periods as outlined in Table 2. Du...
Sample 1
Overall Study Design. This is a Phase 2a, randomized, double‑blind, placebo-controlled, multicenter, 12-week study to evaluate the efficacy and safety of RIST4721 QD in subjects with moderate-to-severe HS. Approximately 33 subjects are planned to be enrolled (approximately 22 subjects expected in the RIST4721 group and 11 subjects in the placebo group). The study will consist of a screening period, a treatment period, and a follow-up period. Study schema is shown in Section 1.2. Subjects will be evaluated throughout the study as specified in the Schedule of Activities (SoA; Section 1.3). After signing an informed consent form (ICF), subjects will be screened for study eligibility over 4 weeks. On Day 1 (baseline visit), eligible subjects will be randomized in 2:1 ratio to receive oral study treatment for 12 weeks: • RIST4721 400 mg QD • Placebo QD All subjects who remain on study treatment through and including Week 12 will be asked to return for a follow-up visit, approximately 4 weeks after their last dose of study treatment, to assess safety and efficacy. Subjects who permanently discontinue study treatment will be followed as described in Section 7.1.
Sample 1
Overall Study Design. The overall study design is described in the master protocol. In this cohort, all patients will receive treatment with TSR-042, bevacizumab, and niraparib (collectively referred to as “study treatment”) beginning on Cycle 1/Day 1 using the regimen detailed in Figure 1. As described in Section 5.1.6, combination treatment with TSR-042, bevacizumab, and niraparib is currently being assessed in ongoing Study 0000-00-000 (NCT03307785). If results from that study are not available at the initiation of treatment for this cohort, an interim safety analysis will be performed after a total of 12 patients are enrolled between Cohorts A and B and have completed 2 cycles of therapy. If results from Study 0000-00-000 are available and support the feasibility of the outlined starting dose regimens, the safety interim analysis will not be performed.
Sample 1
Overall Study Design. The overall sequence of study events is shown in Figure 1. During Screening, patients will have their SOC vasopressors titrated to an age-, size-, and disease-appropriate MAP (Appendix A, Xxxxxxxxx 2013) at the discretion of the Investigator. A minimum titration period of 2 hours, and a maximum of 48 hours, is required. The Screening MAP is calculated as the average of at least two once-hourly MAP readings during SOC vasopressor titration, and within 24 hours prior to LJPC-501 treatment initiation. In the 15 minutes prior to initiation of LJPC-501 dosing, a baseline MAP will be documented. The Baseline MAP is the average of 3 recorded MAP values documented within 15 minutes prior to initiation of LJPC-501 (ie, at approximately -15 minutes, -5 minutes, and 0 minutes or just prior to initiation of LJPC-501 administration). After obtaining informed consent from the patients’ parent(s) or legal guardian(s), assent from the patients (per institutional requirements, as age appropriate, if possible), and confirmation of eligibility, patients will begin LJPC-501 treatment at a dose rate of 5 ng/kg/min. The goal at Hour 2 of LJPC-501 administration is to increase the Baseline MAP by 25% or to decrease the sum XXX by 25%. The LJPC-501 dose will be titrated during this period according to the guidelines in Section 8.3, to achieve a MAP above baseline, but less than 90 mmHg. Throughout treatment, the LJPC-501 dose rate may be increased to a maximum rate of 40 ng/kg/min, and decreased to a minimum of 1.25 ng/kg/min. If MAP exceeds 90 mmHg, SOC vasopressors should be down-titrated first, then LJPC-501 should be down-titrated if MAP remains ≥ 90 mmHg. Any decision to increase the dose rate above 40 ng/kg/min must be made in consultation with Sponsor. With Sponsor approval, the dose rate may be increased to a maximum of 80 ng/kg/min. Unless adjustment is required for safety reasons, SOC vasopressor dosing should be decreased, but not increased, during the first 2 hours of LJPC-501 treatment (ie, up to the Hour 2 time point). MAP should not be allowed to decrease below baseline. A schedule of study procedures is shown in Table 4. Patients will be monitored for hemodynamic xxxxx xxxxx (MAP, HR) at Screening and at approximately -15, -5 and 0 minutes (or just prior to initiation of LJPC-501 dosing) to establish the Baseline MAP value. MAP should be assessed once every 5 minutes during the first 15 minutes of LJPC-501 treatment, then once every 15 minutes up to the Hour 2 tim...
Sample 1
AutoNDA by SimpleDocs
Overall Study Design. This is a prospective cohort study comparing an ultra-low dose of 0.1 mL Magtrace® with the dual technique with Tc99 +/- blue dye for SLN detection with a non-inferiority design. There is no randomisation but instead every person is their own control, i.e., the patient will have the SLN identified with both tracer methods. This study design has already been used in several international studies and 220 persons will be included at four study sites, during 18 months. Skin staining will be documented at the first follow up at four weeks with measurements of size of staining performed and documented with a photograph if staining is present for either SPIO or blue dye. Skin staining will be followed for three years after surgery. Those with a remaining skin staining at the routine 12 months follow up will be followed by telephone interview or physical visit at 24 and 36 months. Furthermore, up to 50 persons will be included for secondary objective A, for evaluation of MRI artefacts in the operated breast at 3-6, 12, and 24 months. All MRI and corresponding mammograms will be evaluated centrally regarding artefacts and breast density.
Sample 1

Related to Overall Study Design

  • Study Design This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Research Design The data generated by excavations at the prehistoric site(s) will be used to examine at least three topics: (1) chronology; (2) technology; and (3) subsistence practices. Insights into changing patterns of community organization may also be granted, as may insights into changes in social organization. The data recovered will then be compared to data from other regional sites.

  • Development Area 10.4. The Development Area shall encompass all Deposits to be produced.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Program Design The County Human Resources Department will operate a Catastrophic Leave Bank which is designed to assist any County employee who has exhausted all paid accruals due to a serious or catastrophic illness, injury, or condition of the employee or family member. The program establishes and maintains a Countywide bank wherein any employee who wishes to contribute may authorize that a portion of his/her accrued vacation, compensatory time, holiday compensatory time or floating holiday be deducted from those account(s) and credited to the Catastrophic Leave Bank. Employees may donate hours either to a specific eligible employee or to the bank. Upon approval, credits from the Catastrophic Leave Bank may be transferred to a requesting employee's sick leave account so that employee may remain in paid status for a longer period of time, thus partially ameliorating the financial impact of the illness, injury, or condition. Catastrophic illness or injury is defined as a critical medical condition, a long-term major physical impairment or disability which manifests itself during employment.

  • Annual Work Plan and Budget 1. The Recipient shall, not later than November 30th of each year, prepare and furnish to the Association an annual work plan and budget (“Annual Work Plan and Budget”) for the Project for the subsequent year, said Annual Work Plan and Budget of such scope and detail as the Association shall have reasonably requested.

Time is Money Join Law Insider Premium to draft better contracts faster.